Oncology On The Go

This week, CancerNetwork spoke with Don Dizon, MD, about certain unique challenges LGBTQ+ patients face when navigating through their cancer journey, and how providers can improve these experiences. The director of women’s cancers at the Lifespan Cancer Institute, director of medical oncology at Rhode Island Hospital, and professor of medicine at the Warren Alpert Medical School of Brown University in Providence, touched on overcoming barriers in clinical cancer research, creating a gender-affirming environment for patients, and other important topics for treating LGBTQ+ patients with cancer.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

The final episode of CancerNetwork’s 4-part series on small cell lung cancer (SCLC) welcomes back Wade Iams, MD, a thoracic medical oncologist at the Vanderbilt University Medical Center. In this conversation, Iams looks to the future of SCLC treatments, touching on topics including extending response durations for patients, emerging therapies for extensive stage SCLC, exciting research on the horizon, and more.
Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.
Check out the previous podcast episodes in this series:·      Episode 1: First-Line Therapeutic Options in Small Cell Lung Cancer

·      Episode 2: Treatment Options for Relapsed/Refractory Small Cell Lung Cancer

·      Episode 3: Practical Considerations for Small Cell Lung Cancer Therapeutic Options

Jun Gong, MD, discussed his perspective piece from the October issue of the journal ONCOLOGY, titled “An Evolving Relationship Between Medical Oncologists and Genetic Counselors in Prostate Cancer.” Gong, a practicing medical oncologist who specializes in the treatment of genitourinary cancers at Cedars-Sinai Medical Center, commented on a review article previously examined on this podcast with Alexandra Sokolova, MD, titled “Germline Testing in Prostate Cancer: When and Who to Test.”
The review article focuses on the treatment implications of germline testing and how this type of testing is becoming more commonplace. Gong’s perspective applauds Sokolova and her colleagues for their work and expands on the necessary relationship between medical oncologists and genetic counselors to effectively treat patients with prostate cancer.
Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

In the third part of a 4-part series on small cell lung cancer (SCLC), CancerNetwork spoke with Wade Iams, MD, a thoracic medical oncologist at the Vanderbilt University Medical Center. The conversation focused on the toxicities of treatment options, quality of life for patients, and how Iams suggests managing and mitigating those events for individuals with SCLC. Some of the agents and regimens discussed include lurbinectedin and trilaciclib, as well as chemotherapy and immunotherapy.
Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.
Check out the previous podcast episodes in this series:·      Episode 1: First-Line Therapeutic Options in Small Cell Lung Cancer

·      Episode 2: Treatment Options for Relapsed/Refractory Small Cell Lung Cancer

This week’s conversation focuses on TrialJectory, a digital health company that utilizes artificial intelligence to inform patients with cancer on their treatment journey. CancerNetwork spoke with Tzvia Bader, CEO and co-founder of TrialJectory, and Karine Perreault, who recently was diagnosed with breast cancer and is on the TrialJectory platform.

The conversation touches on the perceived disconnect between the pharmaceutical industry and patients, the need to remove barriers to access testing, and the action items they thinks need to be prioritized to improve access for women with cancer.

Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

In the second part of a 4-part series on small cell lung cancer, CancerNetwork continued its conversation with Wade Iams, MD, a thoracic medical oncologist at the Vanderbilt University Medical Center. Iams turned the attention to different treatment options for patients with relapsed/refractory small cell lung cancer. Among others, Iams touched on lurbinectedin, topotecan, and some of the crucial clinical trials associated with treatment options for small cell lung cancer, including a phase 2 basket trial and phase 3 ATLANTIS trial examining lurbinectedin.
Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.
Check out the first episode of this series on first-line therapeutic options in small cell lung cancer.

CancerNetwork looks at research from the October issue of the journal ONCOLOGY, titled “Value of Geriatric Assessment in Patients With Genitourinary Carcinoma.” Lead author, Quirin Zangl, MD, from the Department of Neuroanesthesia, at the Christian Doppler Hospital in Salzburg, Austria, spoke in detail about the manuscript.
The research featured 111 patients with urogenital carcinomas with the goal of evaluating comprehensive geriatric assessment tools to better guide these individuals. Patients were divided into 2 groups, which were prostate cancer (n = 88) and distal urinary tract cancer (n = 29). Overall, the relationships between comprehensive geriatric assessment tools and complications, hospital duration, death rate, and baseline characteristics were analyzed.

Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

This week, CancerNetwork looks at an article from the October issue of the journal ONCOLOGY, titled “Germline Testing in Prostate Cancer: When and Who to Test.” CancerNetwork spoke with one of the authors of this article, Alexandra Sokolova, MD, an assistant professor at Oregon Health & Science University.
Sokolova detailed the article, which summarizes germline testing recommendations for prostate cancer, specifically looking at the recently updated NCCN guidelines, as well as describing care models for providing counsel and testing for patients.

Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

In this special episode of the "Oncology Peer Review On-The-Go" podcast, CancerNetwork spoke with Wade Iams, MD, a thoracic medical oncologist at the Vanderbilt University Medical Center, about therapeutic advances for small cell lung cancer. Iams discussed the current first-line therapies for small cell lung cancer, the IMpower133 and CASPIAN trials, and the factors considered for treating patients in the first-line setting. 

Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

As part of its OncView video series, CancerNetwork spoke with Connie Batlevi, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, about recent updates in therapies for relapsed or refractory follicular lymphoma. Batlevi discussed the current treatment options for this disease, as well as third-line therapies, tazemetostat, and sequencing changes.
In the video series, Batlevi discussed the following:
·      Current Treatment Options and Considerations for Relapsed/Refractory Follicular Lymphoma

·      Third-Line Therapies in R/R FL

·      Use of Tazemetostat in R/R FL

·      Sequencing Changes in R/R FL Therapies

To watch more videos in CancerNetwork®’s OncView™ series, visit cancernetwork.com/oncview.